Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, has announced significant progress in its Phase 3 program for HLP003, a potential treatment for major depressive disorder. The company completed enrollment in APPROACH, the first pivotal study, and is on track to report topline data in the fourth quarter of 2026. Enrollment is also underway in EMBRACE, the second pivotal study, while participants continue to roll over into the EXTEND long-term safety study. These milestones underscore the company's commitment to addressing the substantial unmet need in mental health care.
The company also provided updates on its pipeline. HLP004, a candidate for generalized anxiety disorder, is advancing following positive Phase 2 results that demonstrated statistically significant and clinically meaningful improvements. The design for the next study is expected to be completed by the end of the third quarter. Additionally, Helus Pharma is progressing HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027.
Financially, Helus Pharma reported cash of $166.4 million as of June 30, 2026, and a quarterly net loss of $47.8 million, compared with $24.6 million in the same period last year. Cash-based operating expenses increased to $37.5 million from $23.9 million, driven by the advancement of the Phase 3 trials. This investment reflects the company's strategic focus on bringing novel therapies to market.
The importance of these developments lies in the potential of HLP003 to offer a new treatment option for patients with major depressive disorder who have not responded adequately to existing therapies. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address a serious condition. The completion of enrollment in the first pivotal study is a critical step toward regulatory submission and eventual availability to patients.
Helus Pharma, formerly known as Cybin Inc., is dedicated to developing proprietary serotonergic agonists that aim to promote neuroplasticity and provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland, and is committed to advancing its research portfolio.
As the company moves forward, the upcoming topline data in Q4 2026 will be a key catalyst for investors and the medical community. Positive results could position HLP003 as a first-in-class adjunctive treatment for major depressive disorder, potentially transforming the treatment landscape. The company's progress also underscores the growing interest in psychedelic-inspired therapies for mental health conditions.
For more information, visit the company's newsroom at https://ibn.fm/yfpOW.
